NSAIDs and Cardiovascular Risk
Am Fam Physician. 2009 Dec 15;80(12):1366-1368.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used effectively for the treatment of pain conditions and inflammation over the past 100 years and are among the most commonly used drugs worldwide. However, during the last decade there have been increased concerns regarding the cardiovascular safety profile of NSAIDs. These concerns have primarily been related to results from studies demonstrating increased cardiovascular risk with cyclooxygenase-2 (COX-2) inhibitors. Recently, there has been accumulating evidence from several large observational studies and meta-analyses that nonselective NSAIDs are also associated with increased cardiovascular risk.
The main action of NSAIDs is inhibition of the COX enzyme that facilitates synthesis of prostaglandins from arachidonic acid. The prostaglandins are mediators of several physiologic functions, including inf lammation, thrombosis, body salt and water homeostasis, blood pressure, and gastric protection.1 COX has two main isoforms, COX-1 and COX-2, both of which are inhibited by NSAIDs, but in varying degrees.
The vascular effect of NSAIDs is mainly mediated by two products of COX prostaglandin synthesis: thromboxane A2 (TXA2), a vasoconstrictor and potent stimulator of platelet aggregation modulated by the COX-1 isoform, and prostaglandin I2 (PGI2), a potent vasodilator and inhibitor of platelet function predominantly regulated by the COX-2 isoform. TXA2 increases renal salt and fluid retention, increases blood pressure, and enhances myocardial and vascular remodeling, whereas PGI2 facilitates renal salt and fluid excretion and lowers systemic blood pressure. Equilibrium between TXA2 and PGI2 exists in the healthy vascular system, and it has been proposed that NSAIDs, in varying degrees, tip the TXA2/PGI2 balance, thereby increasing cardiovascular risk.
Although studies have demonstrated increased cardiovascular risk with rofecoxib2 (not available in the United States) and other COX-2 inhibitors,3–7 traditional nonselective NSAIDs have been used uncritically for decades with a lack of randomized studies regarding cardiovascular safety. However, several large observational studies and meta-analyses have demonstrated increased cardiovascular risk with nonselective NSAIDs.5,6,8-10
Risk profiles of NSAIDs vary depending on the degree to which individual formulations inhibit the COX-1 or COX-2 isoforms. Hence, nonselective NSAIDs with high COX-2 inhibition (e.g., diclofenac [Cataflam]) seem to have higher cardiovascular risk, whereas nonselective NSAIDs with high COX-1 inhibition (e.g., naproxen [Naprosyn], aspirin, ibuprofen) seem to have higher gastrointestinal risk.1
The primary focus of discussions on cardiovascular risk has been on thrombotic risk. However, NSAIDs can increase the risk of fluid retention and edema, and destabilize and worsen preexisting heart failure. Accordingly, international guidelines have advocated caution when using NSAIDs in persons with heart failure.11 Furthermore, NSAIDs have been shown to influence renal function by decreasing renal perfusion and glomerular filtration rate; cause interstitial nephritis; increase blood pressure; and, in persons with preexisting hypertenion, destabilize blood pressure control.12 Several studies have demonstrated that, in persons with established cardiovascular disease or increased cardiovascular risk, NSAIDs are even more harmful with regards to cardiovascular adverse events.7–9,13
Although current evidence points to increased cardiovascular risk with NSAIDs, a total abandonment of NSAID use is not likely or possible. There will always be groups of patients with pain conditions who must take NSAIDs. Nevertheless, there is a need to focus on the balance between risk and benefit before initiating NSAID treatment. This is especially important in persons with established cardiovascular disease in whom alternative pain treatment with lower cardiac risk (e.g., acetaminophen, weak opiates) should always be the first choice. In persons needing NSAID treatment, NSAIDs with the highest COX-1 selectivity (e.g., naproxen, ibuprofen, aspirin) should be preferred and used in the lowest dosages and for the shortest durations possible. For stronger analgesic effect, a combination with other types of analgesics should be considered.
It is also important to consider the value of nonpharmacologic therapeutic measures, such as physiotherapy and physical exercise, as supplements to analgesic therapy.
Epidemiologic studies have demonstrated extensive use of prescription NSAIDs in the general population, as well as in persons with established cardiac disease.8,9,14 Also, in many countries, NSAIDs are sold without a prescription, expert advice, limits on their use, or information on potential adverse effects. This indicates the need for reevaluation of current treatment strategies regarding NSAID use and the misconception that NSAIDs are harmless for everyone.15
REFERENCESshow all references
1. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15....
2. Bombardier C, Laine L, Reicin A, et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520–1528.
3. Bresalier RS, Sandler RS, Quan H, et al., for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N Engl J Med. 2006;355(2):221.] N Engl J Med. 2005;352(11):1092–1102.
4. Solomon SD, McMurray JJ, Pfeffer MA, et al., for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080.
5. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308.
6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–1644.
7. Solomon SD, Wittes J, Finn PV, et al., for the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104–2113.
8. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective non-steroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906–2913.
9. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–149.
10. Fosbøl EL, Gislason GH, Jacobsen S, et al. Risk of myo-cardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–197.
11. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.
12. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002;89(6A):18D–25D.
13. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777–784.
14. Fosbøl EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf. 2008;17(8):822–833.
15. Rostom A, Moayyedi P, Hunt R, for the Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gas-troprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481–496.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 15, 2017
Access the latest issue of American Family Physician